LeoLuznikMD
Hematology • Houston, TXHematologic Oncology
Professor and Chief, Hematology and Oncology Department of Medicine
Dr. Luznik is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Department of Internal Medicine, Section of Hematology and Oncology
1 Baylor Plaza; ABBR, R 514, Houston, Texas
Houston, TX 77030
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1998 - 2000- Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1997 - 1998
University of Arizona College of Medicine-TucsonResidency, Internal Medicine, 1994 - 1997
UC San Diego Medical Center - HillcrestPost-Doctoral Fellowship, 1991 - 1994
University of Zagreb Faculty of MedicineClass of 1990
Certifications & Licensure
CA State Medical License 1996 - Present
MD State Medical License 1997 - 2026
TX State Medical License 2024 - 2026
Clinical Trials
- Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer Start of enrollment: 2004 Jun 01
- Adoptive Immunotherapy With Activated Marrow Infiltrating Lymphocytes and Cyclophosphamide Graft-Versus-Host Disease Prophylaxis in Patients With Relapse of Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation Start of enrollment: 2015 May 28
- Calcineurin Inhibitor-Free Interventions BMT CTN 1301 for Prevention of Graft-versus-Host Disease (BMT CTN 1301) Start of enrollment: 2015 Aug 01
Publications & Presentations
PubMed
- Chronic graft-versus-host disease: unresolved complication or ancient history?Joseph A Pidala, Ted A Gooley, Leo Luznik, Bruce R Blazar
Blood. 2024-09-26 - 2 citationsCD8+ T-cell differentiation and dysfunction inform treatment response in acute myeloid leukemia.Francesco Mazziotta, Luca Biavati, Joseph Rimando, Sergio Rutella, Nicholas Borcherding
Blood. 2024-09-12 - 6 citationsTargeting PRMT9-mediated arginine methylation suppresses cancer stem cell maintenance and elicits cGAS-mediated anticancer immunity.Haojie Dong, Xin He, Lei Zhang, Wei Chen, Yi-Chun Lin
Nature Cancer. 2024-04-01
Journal Articles
- The European Society for Blood and Marrow Transplantation (EBMT) Consensus Recommendations for Donor Selection in Haploidentical Hematopoietic Cell TransplantationLeo Luznik, Karen Ballen, Asad Bashey, Hillard M Lazarus, Bipin N Savani, Rizwan Romee, Ephraim J Fuchs, Nature
- Small-Molecule BCL6 Inhibitor Effectively Treats Mice with Non-Sclerodermatous Chronic Graft-Versus-Host DiseaseJoseph H Antin, Bruce Blazar, Leo Luznik, John Koreth, Ivan Maillard, Robert J Soiffer, James E Bradner, Jonathan S Serody, Jerome Ritz, Blood
Abstracts/Posters
- Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AMLLeo Luznik, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (_6...Leo Luznik, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- BMT CTN 1803: Haploidentical Natural Killer Cells (CSTD002) to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)Leo Luznik, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Press Mentions
Short Telomere Syndromes Cause a Primary T Cell ImmunodeficiencyOctober 22nd, 2020
Drug Regimen Enough to Control Immune Disease After Some Bone Marrow TransplantsOctober 8th, 2014- How Common Chemo Drug Thwarts Graft Rejection in Bone Marrow TransplantsNovember 13th, 2013
- Join now to see all
External Links
- Johns Hopkins Physicianshttp://www.hopkinsmedicine.org/leonido-luznik
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
